Biotherapeutics Group, National Institute of Biological Standards and Control/Health Protection Agency, Potters Bar, Hertfordshire, UK.
Retrovirology. 2011 Feb 3;8(1):8. doi: 10.1186/1742-4690-8-8.
Vaccination with live attenuated SIV can protect against detectable infection with wild-type virus. We have investigated whether target cell depletion contributes to the protection observed. Following vaccination with live attenuated SIV the frequency of intestinal CD4+CCR5+ T cells, an early target of wild-type SIV infection and destruction, was determined at days 3, 7, 10, 21 and 125 post inoculation.
In naive controls, modest frequencies of intestinal CD4+CCR5+ T cells were predominantly found within the LPL TTrM-1 and IEL TTrM-2 subsets. At day 3, LPL and IEL CD4+CCR5+ TEM cells were dramatically increased whilst less differentiated subsets were greatly reduced, consistent with activation-induced maturation. CCR5 expression remained high at day 7, although there was a shift in subset balance from CD4+CCR5+ TEM to less differentiated TTrM-2 cells. This increase in intestinal CD4+CCR5+ T cells preceded the peak of SIV RNA plasma loads measured at day 10. Greater than 65.9% depletion of intestinal CD4+CCR5+ T cells followed at day 10, but overall CD4+ T cell homeostasis was maintained by increased CD4+CCR5- T cells. At days 21 and 125, high numbers of intestinal CD4+CCR5- naive TN cells were detected concurrent with greatly increased CD4+CCR5+ LPL TTrM-2 and IEL TEM cells at day 125, yet SIV RNA plasma loads remained low.
This increase in intestinal CD4+CCR5+ T cells, following vaccination with live attenuated SIV, does not correlate with target cell depletion as a mechanism of protection. Instead, increased intestinal CD4+CCR5+ T cells may correlate with or contribute to the protection conferred by vaccination with live attenuated SIV.
接种活减 SIV 可预防野生型病毒的可检测感染。我们研究了靶细胞耗竭是否有助于观察到的保护。接种活减 SIV 后,于接种后第 3、7、10、21 和 125 天测定肠道 CD4+CCR5+T 细胞的频率,这是野生型 SIV 感染和破坏的早期靶细胞。
在未感染对照中,肠道 CD4+CCR5+T 细胞的适度频率主要存在于 LPL TTrM-1 和 IEL TTrM-2 亚群中。第 3 天,LPL 和 IEL CD4+CCR5+TEM 细胞显著增加,而分化程度较低的亚群则大大减少,这与激活诱导的成熟一致。第 7 天 CCR5 表达仍然很高,尽管 CD4+CCR5+TEM 从 CD4+CCR5+TEM 到分化程度较低的 TTrM-2 细胞的亚群平衡发生了转移。肠道 CD4+CCR5+T 细胞的增加先于第 10 天测量的 SIV RNA 血浆负荷峰值。第 10 天肠道 CD4+CCR5+T 细胞的耗竭率大于 65.9%,但通过增加 CD4+CCR5-T 细胞维持了总 CD4+T 细胞的稳态。第 21 和 125 天,在第 125 天检测到大量肠道 CD4+CCR5-幼稚 TN 细胞,同时 LPL TTrM-2 和 IEL TEM 细胞的 CD4+CCR5+细胞数量大大增加,但 SIV RNA 血浆负荷仍较低。
活减 SIV 接种后肠道 CD4+CCR5+T 细胞的增加与作为保护机制的靶细胞耗竭无关。相反,肠道 CD4+CCR5+T 细胞的增加可能与活减 SIV 接种赋予的保护相关或有助于保护。